FDA approves IND application for Ph 1 trial of KGX105 monotherapy in locally advanced or metastatic solid tumors

Dr. Weidong Jiang, Chief Executive Officer of KangaBio, commented: “The FDA’s clearance of KGX105, our second pipeline candidate, for clinical trials marks a pivotal moment in the company’s growth and reflects the increasing maturity of our prodrug platform technology. We look forward to thoroughly evaluating the safety and preliminary efficacy of KGX105 in this Phase 1 study, which will lay a solid foundation for its continued clinical development. The encouraging early clinical results from KGX101 have further validated our prodrug platform, offering valuable insights and confidence as we advance our pipeline. We extend our sincere gratitude to both existing and new investors for their continued trust and support. We are committed to accelerating the progress of our clinical programs and bringing new treatment hope to cancer patients around the world.”

Share:

More News

Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20

“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of

“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence

“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib